卡非佐米诱发的血栓性微血管病:基于病例的回顾。

Q1 Medicine

Hematology/ Oncology and Stem Cell Therapy Pub Date : 2023-05-23 DOI:10.1016/j.hemonc.2020.07.001

Nishant Jindal, Aditya Jandial, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Ritambhra Nada, Jasmine Sethi, Jasmina Ahluwalia, Pankaj Malhotra

{"title":"卡非佐米诱发的血栓性微血管病:基于病例的回顾。","authors":"Nishant Jindal, Aditya Jandial, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Ritambhra Nada, Jasmine Sethi, Jasmina Ahluwalia, Pankaj Malhotra","doi":"10.1016/j.hemonc.2020.07.001","DOIUrl":null,"url":null,"abstract":"Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.","PeriodicalId":39226,"journal":{"name":"Hematology/ Oncology and Stem Cell Therapy","volume":"16 4","pages":"426-431"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hemonc.2020.07.001","citationCount":"10","resultStr":"{\"title\":\"Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.\",\"authors\":\"Nishant Jindal, Aditya Jandial, Arihant Jain, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Ritambhra Nada, Jasmine Sethi, Jasmina Ahluwalia, Pankaj Malhotra\",\"doi\":\"10.1016/j.hemonc.2020.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.\",\"PeriodicalId\":39226,\"journal\":{\"name\":\"Hematology/ Oncology and Stem Cell Therapy\",\"volume\":\"16 4\",\"pages\":\"426-431\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.hemonc.2020.07.001\",\"citationCount\":\"10\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematology/ Oncology and Stem Cell Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.hemonc.2020.07.001\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematology/ Oncology and Stem Cell Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.hemonc.2020.07.001","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 10

摘要

Carfilzomib是一种不可逆蛋白酶体抑制剂，目前被批准用于治疗复发性多发性骨髓瘤。在一些病例报告中，它被认为是血栓性微血管病(TMA)的一个原因。卡非佐米相关TMA的发生率、危险因素和治疗方法尚不清楚。在这里，我们描述了一位58岁男性患者的临床表现和结果，活检证实TMA发生在卡非佐米为基础的治疗后。我们还回顾了已发表的关于卡非佐米相关TMA的发病率、危险因素、治疗方案和结局的文献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Carfilzomib-induced Thrombotic Microangiopathy: A Case Based Review.

Carfilzomib is an irreversible proteasome inhibitor currently approved for the treatment of relapsed multiple myeloma. It has been implicated as a cause of thrombotic microangiopathy (TMA) in several case reports. The incidence, risk factors, and treatment of carfilzomib-related TMA remain unclear. Here we describe the clinical presentation and outcome of a 58-year-old man with biopsy-proven TMA that occurred following treatment with carfilzomib-based therapy. We also reviewed the published literature with regard to the incidence, risk factors, treatment options, and outcome of carfilzomib-related TMA.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Hematology/ Oncology and Stem Cell Therapy Medicine-Hematology

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

27 weeks

期刊介绍： Hematology Oncology and Stem Cell Therapy is an international, peer-reviewed, open access journal that provides a vehicle for publications of high-quality clinical as well as basic science research reports in hematology and oncology. The contents of the journal also emphasize the growing importance of hematopoietic stem cell therapy for treatment of various benign and malignant hematologic disorders and certain solid tumors.The journal prioritizes publication of original research articles but also would give consideration for brief reports, review articles, special communications, and unique case reports. It also offers a special section for clinically relevant images that provide an important educational value.